Everything below concerns adipose tissue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Archaeol's biosynthesis proceeds by a multistep process mediated by several enzymes. In simplified terms, glycerol 1-phosphate is etherified to two geranylgeranyl substituents contributed by geranylgeranyl pyrophosphate. The double bonds are reduced by nicotinamide and flavins. The phosphate group is subject to modification. Archaea utilize biosynthetic pathways of isoprenoids that is distinct compared to bacteria and eukarya. The C5 precursors to the geranylgeranyl chains are isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are produced by modified mevalonic acid pathway.
In the Middle Ages the regions situated on the mountainous border of the Duchy and the Kingdom of Bohemia (Crown of Saint Václav) had since the Migration Period been settled mainly by western Slavic Czechs. Along the Bohemian Forest in the west, the Czech lands bordered on the German Slavic tribes (German Sorbs) stem duchies of Bavaria and Franconia; marches of the medieval German kingdom had also been established in the adjacent Austrian lands south of the Bohemian-Moravian Highlands and the northern Meissen region beyond the Ore Mountains. In the course of the Ostsiedlung (settlement of the east), German settlement from the 13th century onwards continued to move into the Upper Lusatia region and the duchies of Silesia north of the Sudetes mountain range. From as early as the second half of the 13th century onwards these Bohemian border regions were settled by ethnic Germans, who were invited by the Přemyslid Bohemian kings—especially by Ottokar II (1253–1278) and Wenceslaus II (1278–1305). After the extinction of the Přemyslid dynasty in 1306, the Bohemian nobility backed John of Luxembourg as king against his rival Duke Henry of Carinthia. In 1322, King John of Bohemia acquired (for the third time) the formerly Imperial Egerland region in the west and vassalized most of the Piast Silesian duchies, as acknowledged by King Casimir III of Poland by the 1335 Treaty of Trentschin. His son, Bohemian King Charles IV, was elected King of the Romans in 1346 and crowned Holy Roman Emperor in 1355.
Corticotropin-releasing hormone (CRH), which regulates ACTH secretion from the anterior pituitary gland Somatostatin, which regulates growth hormone secretion from the anterior pituitary gland Thyrotropin-releasing hormone (TRH), which regulates TSH and prolactin secretion
Sand dollars diverged from the other irregular echinoids, namely the cassiduloids, during the early Jurassic, with the first true sand dollar genus, Togocyamus, arising during the Paleocene. Soon after Togocyamus, more modern-looking groups emerged during the Eocene. Sand dollars are small in size, averaging from 80 to 100 mm (3 to 4 inches). As with all members of the order Clypeasteroida, they possess a rigid skeleton called a test. The test consists of calcium carbonate plates arranged in a fivefold symmetric pattern. The tests of certain species of sand dollar have slits called lunules that can help the animal stay embedded in the sand to stop it from being swept away by an ocean wave. In living individuals, the test is covered by a skin of velvet-textured spines which are covered with very small hairs (cilia). Coordinated movements of the spines enable sand dollars to move across the seabed. The velvety spines of live sand dollars appear in a variety of colors—green, blue, violet, or purple—depending on the species. Individuals which are very recently dead or dying (moribund) are sometimes found on beaches with much of the external morphology still intact. Dead individuals are commonly found with their empty test devoid of all surface material and bleached white by sunlight. The bodies of adult sand dollars, like those of other echinoids, display radial symmetry. The petal-like pattern in sand dollars consists of five paired rows of pores. The pores are perforations in the endoskeleton through which podia for gas exchange project from the body.
Sources: en.wikipedia.org
Tyne and Wear () is a ceremonial county in North East England. It borders Northumberland to the north and County Durham to the south. The county contains the two cities of Newcastle upon Tyne and Sunderland. The notable towns in the county are Birtley, Blaydon Felling, Gateshead, Hebburn, Hetton-le-Hole, Houghton-le-Spring, Jarrow, Killingworth, North Shields, South Shields, Tynemouth, Wallsend, Washington and Whitley Bay. The county is largely urbanised, with an area of 540 square kilometres (210 sq mi) and an estimated population of 1,178,389 in 2024. Newcastle is on the north bank of the River Tyne in the centre of the county, and Gateshead opposite on the south bank. South Shields lies in the east at the river's mouth, and the city of Sunderland in the south-east at the mouth of the River Wear. Nearly all of the county's settlements belong to the Tyneside or Wearside conurbations, the latter of which extends into County Durham. For local government purposes Tyne and Wear comprises five metropolitan boroughs: Gateshead, Newcastle upon Tyne, Sunderland, North Tyneside and South Tyneside. The borough councils collaborate through the North East Combined Authority, which also includes Durham County Council and Northumberland County Council. The county was created in 1974 from south-east Northumberland and north-east County Durham. The most notable geographic features of the county are the River Tyne and River Wear, after which it is named and along which its major settlements developed.
The main function of trypanothione synthase is to use the free energy generated from ATP hydrolysis to conjugate glutathione and spermidine to form the intermediate of glutathionylspermidine and then the final product of trypanothione. It also catalyzes the reverse reaction as well, albeit at a much lower rate. Under conditions found to be the optimum for both the forward and backwards reactions, trypanothione synthase from trypanosoma cruzi was found to have an amidase activity that was only about 1% of the forwards synthetase activity. This low activity can be explained by the blocking of the catalytic Cys in the amidase active site in order for the protein to properly fold. In parasitic kinetoplastids trypanothione synthase activity is key to survival. Due to the need for trypanothione in order to defend against oxidative stresses, and maintain thiol and ribonucleotide metabolism. It was observed that induced knockout of trypanothione synthase through RNA interference caused a reduced growth rate of twofold among trypanosoma brucei due to the immediate disruption of flux through thiol redox. In other similar experiments which observed cell death after knocking out trypanothione synthase, it was shown that after two hours of being exposed to hydrogen peroxide in order to mimic the oxidant attack of phagocytes, the cells which did not contain working trypanothione synthase had a much higher death rate than wild type T. brucei.
For the 2005 sequel The Ring Two, Chase was credited due to the use of archival footage from the first film, although actress Kelly Stables performed all the new on-screen material and motion capture for Samara. Between 2003 and 2004, Chase held a main cast role as Joyce, the quirky girlfriend of the title character, in the Fox period sitcom Oliver Beene. Her other notable credits during this period included the direct-to-video film Beethoven's 5th (2003) and the romantic comedy Carolina (2003), in which she played the younger version of Julia Stiles' character.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.